Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women.
However, its safety and efficacy in increasing bone mineral density in chronic peritoneal
dialysis (PD) patients have not been investigated. Etidronate, another bisphosphonate, can
suppress the extent of coronary artery calcification in chronic hemodialysis patients. The
hypothesis of this study is that alendronate can increase bone mineral density and suppress
aortic and coronary artery calcification in chronic peritoneal dialysis patients.